Cochrane · systematic review · CD013028
Clonazepam monotherapy for treating people with newly diagnosed epilepsy
Brigo, F, Igwe, SC, Bragazzi, NL, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
1
No studies
9
Included studies
NR
No studies 9 · 90%Ungraded 0 · 0%Very low 1 · 10%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyClonazepam compared to carbamazepine for treating people with newly diagnosed epilepsy
Population: people with newly diagnosed epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants seizure‐free at 12 months after randomization ‐ not reported Clonazepam vs carbamazepine | no estimate extracted | NR | No studies |
Proportion of participants seizure‐free at 24 months after randomization ‐ not reported Clonazepam vs carbamazepine | no estimate extracted | NR | No studies |
Proportion of responders (those with at least a 50% reduction in seizure frequency from baseline to end of treatment) Clonazepam vs carbamazepine | no estimate extracted | NR | No studies |
Proportion of participants with treatment‐emergent adverse events (TEAEs) during the treatment period Clonazepam vs carbamazepine | no estimate extracted | NR | No studies |
Proportion of participants with treatment‐emergent adverse events (TEAEs) leading to discontinuation during the treatment period (1 RCT; n = 36) Clonazepam vs carbamazepine | RR 2.61 [0.8, 8.52] | NR | Very low Downgraded: imprecision |
Clonazepam compared to ethosuximide for treating people with newly diagnosed epilepsy
Population: people with newly diagnosed epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants seizure‐free at 12 months after randomization Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants seizure‐free at 24 months after randomization Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of responders (those with at least a 50% reduction in seizure frequency from baseline to end of treatment) Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants with treatment‐emergent adverse events (TEAEs) during the treatment period Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants with TEAEs leading to discontinuation during the treatment period Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Clonazepam compared to carbamazepine for treating people with newly diagnosed epilepsy
Population: people with newly diagnosed epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants seizure‐free at 1 month after randomization № of participants: 30 (1 RCT) Clonazepam vs carbamazepine | RR 1.97 [0.99, 3.94] | NR | Very low Downgraded: imprecision |
Proportion of participants seizure‐free at 3 months after randomization № of participants: 26 (1 RCT) Clonazepam vs carbamazepine | RR 1.19 [0.62, 2.29] | NR | Very low Downgraded: imprecision |
Proportion of participants seizure‐free at 6 months after randomization № of participants: 9 (1 RCT) Clonazepam vs carbamazepine | RR 0.5 [0.09, 2.73] | NR | Very low Downgraded: imprecision |
Proportion of participants seizure‐free at 12 months after randomization ‐ not reported Clonazepam vs carbamazepine | no estimate extracted | NR | No studies |
Proportion of participants seizure‐free at 24 months after randomization ‐ not reported Clonazepam vs carbamazepine | no estimate extracted | NR | No studies |
Proportion of participants with treatment‐emergent adverse events (TEAEs) during the treatment period ‐ not reported Clonazepam vs carbamazepine | no estimate extracted | NR | No studies |
Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) Clonazepam vs carbamazepine | RR 2.61 [0.8, 8.52] | NR | Very low Downgraded: imprecision |
Clonazepam compared to ethosuximide for treating people with newly diagnosed epilepsy
Population: people with newly diagnosed epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of participants seizure‐free at 1 month after randomization Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants seizure‐free at 3 months after randomization Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants seizure‐free at 6 months after randomization Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants seizure‐free at 12 months after randomization Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants seizure‐free at 24 months after randomization Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of responders (those with at least a 50% reduction in seizure frequency from baseline to end of treatment) Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants with treatment‐emergent adverse events (TEAEs) during the treatment period Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |
Proportion of participants with TEAEs leading to discontinuation during the treatment period Clonazepam vs ethosuximide | no estimate extracted | NR | No studies |